Selecta Biosciences, Inc. (Nasdaq:SELB) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions. All of the common stock is being … Continued
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis on silicon, today announced it has expanded its existing relationship with Ginkgo Bioworks, one of its initial Beta access customers, to deliver an additional 300 million base … Continued
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, and Desktop Genetics, a London-based software company, today announced a partnership to provide integrated experiment design and DNA synthesis tools to expedite gene editing research. Desktop Genetics … Continued
View, the leader in dynamic glass, today announced it has completed more than 200 projects in North America, with more than 100 additional projects currently in development. With over 12,000 occupants enjoying View Dynamic Glass across 7 million square feet … Continued
On April 29, 2016, WIRED Health gathered 21 ground breaking speakers to present the future of the healthcare and medical industries. Also, on the Bupa Startup Stage, 18 growth-stage companies presented their ideas, technologies and platforms. Emulate’s President & Chief Scientific Officer – … Continued
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, announced today that it obtained an exclusive license to Anc80, an in silico designed gene therapy vector, from Massachusetts Eye and Ear. Under the agreement, Selecta secures an … Continued
In a cavernous manufacturing plant about 20 miles from Memphis, a vision of the future is humming away. A California start-up called View, which has raised a whopping $500 million from investors including Corning, General Electric and Khosla Ventures, is making … Continued
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced Microsoft Corp. has agreed to purchase ten million long oligonucleotides from Twist Bioscience to encode digital data. “Today, the vast majority of digital data is … Continued
ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced the appointment of Gail L. Brown, M.D. to the position of Chief Medical Officer. Dr. Brown will be responsible for the clinical development of the company’s pipeline of immunotherapies including the … Continued
Twist Bioscience Corporation, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the acquisition of Genome Compiler Corporation, an Israeli-based company providing software for genetic engineers, molecular and synthetic biologists. Twist Bioscience intends to leverage Genome … Continued